143 related articles for article (PubMed ID: 22137848)
21. Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.
Hoenke C; Bouyssou T; Tautermann CS; Rudolf K; Schnapp A; Konetzki I
Bioorg Med Chem Lett; 2009 Dec; 19(23):6640-4. PubMed ID: 19875286
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of new 4,5-3(2H)pyridazinone derivatives and their cardiotonic, hypotensive, and platelet aggregation inhibition activities.
Amin EN; Abdel-Alim AA; Abdel-Moty SG; El-Shorbagi AN; Abdel-Rahman MSh
Arch Pharm Res; 2010 Jan; 33(1):25-46. PubMed ID: 20191341
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.
Zhao LM; Jin HS; Sun LP; Piao HR; Quan ZS
Bioorg Med Chem Lett; 2005 Nov; 15(22):5027-9. PubMed ID: 16169724
[TBL] [Abstract][Full Text] [Related]
24. Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranones with platelet antiaggregating activity.
Di Braccio M; Roma G; Leoncini G; Poggi M
Farmaco; 1995 Oct; 50(10):703-11. PubMed ID: 8590578
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
Ko HH; Hsieh HK; Liu CT; Lin HC; Teng CM; Lin CN
J Pharm Pharmacol; 2004 Oct; 56(10):1333-7. PubMed ID: 15482650
[TBL] [Abstract][Full Text] [Related]
26. 1,2-fused pyrimidines. VI. Substituted 2-amino-4H-pyrido[1,2-a]pyrimidin-4-ones with antiplatelet activity.
Roma G; Di Braccio M; Leoncini G; Aprile B
Farmaco; 1993 Sep; 48(9):1225-38. PubMed ID: 8259980
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs.
Hsieh PW; Chiang SZ; Wu CC; Lo YC; Shih YT; Wu YC
Bioorg Med Chem; 2008 May; 16(10):5803-14. PubMed ID: 18407506
[TBL] [Abstract][Full Text] [Related]
28. [Synthesis of thienopyridine derivatives and its anti-platelet activity in vivo].
Zhou YS; Wang PB; Liu Y; Chen JF; Yue N; Liu DK
Yao Xue Xue Bao; 2011 Jan; 46(1):70-4. PubMed ID: 21465811
[TBL] [Abstract][Full Text] [Related]
29. Association of recurrent cerebral infarction with adenosine diphosphate- and collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin.
Abumiya T; Houkin K
J Stroke Cerebrovasc Dis; 2011; 20(4):319-23. PubMed ID: 20634093
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and inhibitory effects of 1,4,5-trialkyl-2-thioimidazole derivatives on platelet aggregation.
Fatimi J; Lagorce JF; Chabernaud ML; Buxeraud J; Raby C
Boll Chim Farm; 1994 Mar; 133(3):151-5. PubMed ID: 8011274
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation as platelet aggregation inhibitors of 6-phenyl-2,4-substituted-3(2H)-pyridazinones and their rigid analogues benzo[h]cinnolin-3,5-diones.
Dal Piaz V; Ciciani G; Giovannoni MP
Drug Des Discov; 1996 Mar; 14(1):53-75. PubMed ID: 8854045
[TBL] [Abstract][Full Text] [Related]
32. [Synthesis and platelet aggregation inhibitory activity of 6-(4-substituted phenyl)-4,5-dihydro-3(2H)-pyridazinones].
Jiang Q; Sun CS
Yao Xue Xue Bao; 1990; 25(8):598-603. PubMed ID: 2082682
[TBL] [Abstract][Full Text] [Related]
33. 1,5-Benzodiazepines. X. Dialkylamino substituted 1,5-benzodiazepine and [1,2,4]triazolo [4,3-a][1,5] benzodiazepine derivatives with inhibitory activity on PAF-induced platelet aggregation.
Di Braccio M; Roma G; Grossi GC; Leoncini G; Maresca M
Farmaco; 1992 Jan; 47(1):77-90. PubMed ID: 1616579
[TBL] [Abstract][Full Text] [Related]
34. Non-peptide-based new class of platelet aggregation inhibitors: Design, synthesis, bioevaluation, SAR, and in silico studies.
Jaiswal PK; Sharma V; Kumar S; Mathur M; Swami AK; Yadav DK; Chaudhary S
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700349. PubMed ID: 29522645
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
Wang WY; Hsieh PW; Wu YC; Wu CC
Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of copper-aspirin complex on platelet aggregation.
Shen ZQ; Chen ZH; Ma GY; Wang DC; Wu WL; Liu WP; Yang YK; Xiong HZ
Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):358-62. PubMed ID: 10072923
[TBL] [Abstract][Full Text] [Related]
37. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines.
Perry B; Alexander R; Bennett G; Buckley G; Ceska T; Crabbe T; Dale V; Gowers L; Horsley H; James L; Jenkins K; Crépy K; Kulisa C; Lightfoot H; Lock C; Mack S; Morgan T; Nicolas AL; Pitt W; Sabin V; Wright S
Bioorg Med Chem Lett; 2008 Aug; 18(16):4700-4. PubMed ID: 18644721
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of diverse benzo[1,4]oxazin-3-one-based compounds using 1,5-difluoro-2,4-dinitrobenzene.
Yuan Y; Liu G; Li L; Wang Z; Wang L
J Comb Chem; 2007; 9(1):158-70. PubMed ID: 17206844
[TBL] [Abstract][Full Text] [Related]
39. 2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.
Meyers C; Yáñez M; Elmaatougi A; Verhelst T; Coelho A; Fraiz N; Lemière GL; García-Mera X; Laguna R; Cano E; Maes BU; Sotelo E
Bioorg Med Chem Lett; 2008 Jan; 18(2):793-7. PubMed ID: 18053717
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients.
Pulcinelli FM; Pignatelli P; Celestini A; Riondino S; Gazzaniga PP; Violi F
J Am Coll Cardiol; 2004 Mar; 43(6):979-84. PubMed ID: 15028353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
